Form 8-K/A date of report 08-08-24 true 0001069530 0001069530 2024-08-08 2024-08-08
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K/A
(Amendment No. 1)
 
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) August 8, 2024
 
 
Cassava Sciences, Inc.
(Exact name of registrant as specified in its charter)
 
 
Delaware
001-41905
91-1911336
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer Identification Number)
6801 N Capital of Texas Highway, Building 1; Suite 300
Austin, Texas 78731
(Address of principal executive offices, including zip code)
 
(512) 501-2444
(Registrant’s telephone number, including area code)
 
(Former name or former address, if changed since last report.)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
 
 
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange on which registered
Common Stock, $0.001 par value
  
SAVA
  
Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).                                                                                  
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Explanatory Note
 
This Amendment No. 1 to the Current Report on Form 8-K (“Amendment”) of Cassava Sciences, Inc. (the “Company”) is being filed to amend the Current Report on Form 8-K furnished on August 8, 2024 (the “Initial 8-K”) announcing the Company’s financial results for the quarter ended June 30, 2024 solely for the purpose of correcting an error in the Net income (loss) per share, diluted presented for the Six months ended June 30, 2024. No other figures or information in the Initial 8-K are impacted by this correction and no other changes are made to the Initial 8-K.
 
Item 2.02. Results of Operations and Financial Condition.
 
On August 8, 2024, the Company issued a press release announcing financial results for the quarter ended June 30, 2024 (the “Earnings Release”). Within the financial tables included in the Earnings Release, the Company incorrectly presented Net income (loss) per share, diluted for the Six months ended June 30, 2024 as $(1.72). The Company is filing this Amendment to provide the corrected Net income (loss) per share, diluted for the Six months ended June 30, 2024 of $(0.28), which was correctly presented in the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission on August 8, 2024.
 
The information provided in this Amendment is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in such filing.
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
CASSAVA SCIENCES, INC.
Date: August 9, 2024
By:
/s/ Eric J. Schoen
Eric J. Schoen
Chief Financial Officer
 
 
 
v3.24.2.u1
Document And Entity Information
Aug. 08, 2024
Document Information [Line Items]  
Entity, Registrant Name Cassava Sciences, Inc.
Document, Type 8-K/A
Document, Period End Date Aug. 08, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-41905
Entity, Tax Identification Number 91-1911336
Entity, Address, Address Line One 6801 N Capital of Texas Highway
Entity, Address, Address Line Two Building 1; Suite 300
Entity, Address, City or Town Austin
Entity, Address, State or Province TX
Entity, Address, Postal Zip Code 78731
City Area Code 512
Local Phone Number 501-2444
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol SAVA
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Description Form 8-K/A date of report 08-08-24
Amendment Flag true
Entity, Central Index Key 0001069530
Cassava Sciences (NASDAQ:SAVAW)
Historical Stock Chart
From Jul 2024 to Aug 2024 Click Here for more Cassava Sciences Charts.
Cassava Sciences (NASDAQ:SAVAW)
Historical Stock Chart
From Aug 2023 to Aug 2024 Click Here for more Cassava Sciences Charts.